Alkermes expects Q3 2026 total revenues of $450M-$470M as CEO transition and orexin readouts approach

Data ReadoutNeutral

AI Analysis

Alkermes provided Q3 2026 total revenue guidance of $450M-$470M while noting an upcoming CEO transition and anticipated orexin clinical readouts.

Guidance

$450M-$470M Q3 2026

Orexin readouts expected

Importance:5/10

Sentiment:

0.00

guidanceCEO transitiondata readoutorexin

Related Companies

Read the original article

Published by Seeking Alpha Healthcare on July 28, 2026 7:04 PM